ZYVERSA THERAPEUTICS, INC. Deferred Federal, State and Local, Tax Expense (Benefit)
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Deferred Federal, State and Local, Tax Expense (Benefit) of -$6.19 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. deferred federal, state and local, tax expense (benefit) for fiscal 2025 was -$6.19M.
- ZYVERSA THERAPEUTICS, INC. deferred federal, state and local, tax expense (benefit) for fiscal 2024 was -$1.85M.
- ZYVERSA THERAPEUTICS, INC. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was -$23.57M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 1 month | Deferred Federal, State and Local, Tax Expense (Benefit) 11 month | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2025-12-31 | -$6.19M 10-K · filed 2026-03-31 | ||
| 2024-12-31 | -$1.85M 10-K · filed 2026-03-31 | ||
| 2023-12-31 | -$23.57M 10-K · filed 2025-03-27 | ||
| 2022-12-31 | -$186.47K 10-K · filed 2024-03-25 | ||
| 2022-12-12 | -$2.67M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |